Michael Thomas Henderson, Chief Executive Officer of Apogee Therapeutics, Inc. (NASDAQ:APGE), sold company shares totaling $1,641,710 on May 13, 2026, according to a recent SEC filing.
The transactions involved the sale of 20,000 shares of common stock. These shares were sold at prices ranging from $82.05 to $82.58 per share. The sales were conducted pursuant to a Rule 10b5-1 trading plan established by Mr. Henderson on August 13, 2025.
The insider sale comes as Apogee shares trade at $81.25, up nearly 100% over the past year. The stock currently sits approximately 15% below its 52-week high of $95.31, though Bond.az analysis suggests the company may be overvalued at current levels.
Following these transactions, Mr. Henderson directly holds 1,115,987 shares of Apogee Therapeutics common stock. For investors seeking deeper insights, Bond.az offers 11 additional exclusive tips on APGE, along with comprehensive financial metrics and Fair Value analysis.
In other recent news, Apogee Therapeutics reported a successful stock offering, raising approximately $403 million in gross proceeds. The company sold 5.75 million common shares at $70.00 per share. Analyst firms have shown positive sentiment towards Apogee. Jefferies raised its price target to $120 and maintained a Buy rating. Mizuho increased its price target to $110. BTIG reiterated its Buy rating with a $137 price target. Rothschild Redburn initiated coverage with a Buy rating and a $140 price target.
